MRSH Stock Analysis: Marsh & McLennan Companies | NYSE
Insurance Brokers | NYSE, USA | Market Cap: 83.984m USD | 12M Return: -9.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 440M
EPS Trend: 99.6%
Qual. Beats: 7
Rev. Trend: 99.8%
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Marsh & McLennan Companies (NYSE: MRSH) is a global professional services firm offering advisory and insurance solutions across risk, strategy, and people. It operates through two segments: Risk and Insurance Services, which includes insurance and reinsurance broking, risk consulting, actuarial services, and analytics; and Consulting, which provides health, wealth, and career advisory services along with strategic, economic, and brand consulting. Founded in 1871 and headquartered in New York, the firm serves businesses, public entities, insurers, and private clients worldwide.
The company sits within the GICS Financials sector, specifically the Insurance Brokers sub-industry, making it part of a narrow group of large, publicly traded insurance intermediaries. Its business model combines fee-based advisory and consulting revenue with commission-driven brokerage income, and it is generally regarded as one of the largest global players in commercial insurance brokerage alongside other major competitors in the space.
- Hard insurance market lifts Risk and Insurance Services organic growth
- Mercer wealth and benefits segment expands on AUM growth
- M&A activity accelerates in specialty insurance brokerage market
| Net Income: 3.98b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.04 > 1.0 |
| NWC/Revenue: 10.64% < 20% (prev 15.25%; Δ -4.61% < -1%) |
| CFO/TA 0.09 > 3% & CFO 5.08b > Net Income 3.98b |
| Net Debt (22.5b) to EBITDA (6.95b): 3.24 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (484.0m) vs 12m ago -2.22% < -2% |
| Gross Margin: 42.38% > 18% (prev 42.57%; Δ -0.19% > 0.5%) |
| Asset Turnover: 47.27% > 50% (prev 44.06%; Δ 3.21% > 0%) |
| Interest Coverage Ratio: 6.28 > 6 (EBIT TTM 6.04b / Interest Expense TTM 962.0m) |
| A: 0.05 (Total Current Assets 24.3b - Total Current Liabilities 21.4b) / Total Assets 59.7b |
| B: 0.49 (Retained Earnings 29.3b / Total Assets 59.7b) |
| C: 0.10 (EBIT TTM 6.04b / Avg Total Assets 59.1b) |
| D: 0.35 (Book Value of Equity 15.4b / Total Liabilities 44.2b) |
| Altman-Z'' = 2.98 = A |
| DSRI: 0.98 (Receivables 8.94b/8.46b, Revenue 27.9b/25.8b) |
| GMI: 1.00 (GM 42.57% / 42.38%) |
| AQI: 0.99 (AQ_t 0.55 / AQ_t-1 0.56) |
| SGI: 1.08 (Revenue 27.9b / 25.8b) |
| TATA: -0.02 (NI 3.98b - CFO 5.08b) / TA 59.7b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at USD 183.31 with a total of 1,573,524 shares traded. Over the past week, the price has changed by +1.23%, over one month by +10.58%, over three months by +8.34% and over the past year by -9.31%.
Current recommended Stop Loss: 174.20 (which is 5% or 2 ATR below the current price).
Marsh & McLennan Companies has received a consensus analysts rating of 3.61. Therefore, it is recommended to hold MRSH.
- StrongBuy: 6
- Buy: 3
- Hold: 13
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 202.2 | 10.3% |
P/E Trailing = 22.6791
P/E Forward = 17.5439
P/S = 3.0051
P/B = 5.948
P/EG = 1.7545
Revenue TTM = 27.9b USD
EBIT TTM = 6.04b USD
EBITDA TTM = 6.95b USD
Long Term Debt = 18.3b USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.00b USD (from shortTermDebt, last quarter)
Debt = 24.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.85b
Net Debt = 22.5b USD (calculated: Debt 24.2b - CCE 1.70b)
Enterprise Value = 107b USD (84.0b + Debt 24.2b - CCE 1.70b)
Interest Coverage Ratio = 6.28 (Ebit TTM 6.04b / Interest Expense TTM 962.0m)
EV/FCF = 22.34x (Enterprise Value 107b / FCF TTM 4.77b)
FCF Yield = 4.48% (FCF TTM 4.77b / Enterprise Value 107b)
FCF Margin = 17.06% (FCF TTM 4.77b / Revenue TTM 27.9b)
Net Margin = 14.24% (Net Income TTM 3.98b / Revenue TTM 27.9b)
Gross Margin = 42.38% ((Revenue TTM 27.9b - Cost of Revenue TTM 16.1b) / Revenue TTM)
Gross Margin QoQ = 44.07% (prev 45.64%)
Tobins Q-Ratio = 1.78 (Enterprise Value 107b / Total Assets 59.7b)
Interest Expense / Debt = 3.97% (Interest Expense 962.0m / Debt 24.2b)
Taxrate = 23.95% (1.28b / 5.35b)
NOPAT = 4.60b (EBIT 6.04b * (1 - 23.95%))
Current Ratio = 1.14 (Total Current Assets 24.3b / Total Current Liabilities 21.4b)
Debt / Equity = 1.57 (Debt 24.2b / totalStockholderEquity, last quarter 15.4b)
Debt / EBITDA = 3.24 (Net Debt 22.5b / EBITDA 6.95b)
Debt / FCF = 4.73 (Net Debt 22.5b / FCF TTM 4.77b)
Total Stockholder Equity = 15.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.73% (Net Income 3.98b / Total Assets 59.7b)
RoE = 26.42% (Net Income TTM 3.98b / Total Stockholder Equity 15.1b)
RoCE = 18.10% (EBIT 6.04b / Capital Employed (Equity 15.1b + L.T.Debt 18.3b))
RoIC = 11.81% (NOPAT 4.60b / Invested Capital 38.9b)
WACC = 5.37% (E(84.0b)/V(108b) * Re(6.05%) + D(24.2b)/V(108b) * Rd(3.97%) * (1-Tc(0.24)))
Discount Rate = 6.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -88.85 | Cagr: -1.17%
[DCF] Terminal Value 75.76% ; FCFF base≈4.72b ; Y1≈4.84b ; Y5≈5.33b
[DCF] Fair Price = 125.9 (EV 82.6b - Net Debt 22.5b = Equity 60.1b / Shares 477.2m; r=8.35% [WACC [floored]]; 5y FCF grow 2.43% → 2.50% )
EPS Correlation: 99.61 | EPS CAGR: 10.12% | SUE: 1.77 | # QB: 7
Revenue Correlation: 99.76 | Revenue CAGR: 8.89% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.98 | Chg30d=-0.35% | Revisions=+17% | Analysts=21
EPS current Year (2026-12-31): EPS=10.42 | Chg30d=+0.25% | Revisions=+0% | GrowthEPS=+6.9% | GrowthRev=+5.6%
EPS next Year (2027-12-31): EPS=11.36 | Chg30d=+0.35% | Revisions=+17% | GrowthEPS=+9.0% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +18% (up=5, down=3)